林凡

发布者:基础医学院发布时间:2016-03-24浏览次数:18925

林凡,教授,博士,博士生导师,细胞生物学系主任

科学研究方向

1、肿瘤靶向药物的精准与联合治疗

2、通过CRISPR/Cas9的功能基因组筛选恶性肿瘤治疗新靶点

3、脑胶质瘤的治疗与跨血脑屏障药物递送

4、肿瘤、衰老与衰老相关分泌表型

5、肿瘤动物模型

联系方式

通讯:江苏省南京市江宁区龙眠大道101号细胞生物学系,邮编211166

电话:86869472

电邮:linfan@njmu.edu.cn


简介

林凡 南京医科大学细胞生物学系主任,教授,博士生导师,江苏省特聘教授。于浙江大学生命科学院毕业,分别于2008年和2013年获阿姆斯特丹大学医学生物化学硕士和荷兰癌症研究所获临床药理的博士学位。后于华大基因从事基因与基因组分析研究以及新加坡国立大学医学院从事博士后研究,常年致力研究基因组与药物的相互关系。目前主要的研究方向为通过功能基因组学来筛选针对如PTENNF1CDKN2A等关键信号通路发生突变的恶性肿瘤产生合成致死作用的靶向药物/药物靶点。近年来在Clin Cancer Res201720142013),Chem Eng J, Eur J Cancer, Clin and Trans Med, Int J CancerMol Cancer Ther等国际癌症期刊发表一作或通讯20余篇,引用>500次。同时出版英文论著一本,获得国家发明专利授权两项。

 

教育背景及工作经历

1996-2000 于浙江大学获学士学位,专业生物学

2000-2003 于华大基因任基因组分析员

2006-2008 于荷兰阿姆斯特丹大学获科学硕士学位,专业医学生物化学

2009-2013 于荷兰乌特勒支大学-荷兰癌症研究所获博士学位,专业肿瘤临床药理学

 2013-2016于新加坡国立大学任研究员(Research Fellow)

2016-至今 于南京医科大学基础医学院任教授

 

学术兼职

中国转化医学联盟 任理事

江苏省遗传学会  任常务理事 人类遗传专委会副主任

中国环境诱变剂学会致癌 任专业委员会委员

江苏省肿瘤个体化医学协调创新中心脑胶质瘤研究所学术委员会委员


承担科研课题

1. PKMYT1PTEN缺失脑胶质母细胞瘤中高表达并导致WEE1抑制剂耐受的机制研究(32170738)国家自然科学基金委员会面上项目,58万,2022-2026年, 在研,主持

2.针对PTEN突变或缺失恶性脑胶质瘤的多层次靶向药物筛选与研究(81672962),国家自然科学基金委员会面上项目,60万, 2017-2021年,结题,主持

3.脂代谢紊乱疾病的转化医学研究   江苏省科技厅双创团队项目 300万,2018-2021年,结题,参与

4. 恶性脑胶质瘤联合靶向治疗的精准基因分型和疗效预测模型的建立  东南大学-南京医科大学合作研究重点项目,30万, 2019-2022年,结题,主持

5.抗肿瘤靶向小分子药物的个性化治疗   南京医科大学引进人才科研启动基金,100万, 2016-2021结题 主持

 

代表性论文

通讯或第一作者论文

1.Ma Y, Lin C, Liu S, Wei Y, Ji C, Shi F, *Lin F(林凡), *Zhou Z. Radiomics features based on internal and marginal areas of the tumor for the preoperative prediction of microsatellite instability status in colorectal cancer. Front Oncol. 2022 Oct 6;12:1020349. doi: 10.3389/fonc.2022.1020349. IF=5.738(共同通讯作者)

 

2.Wang Q, Li J, Zhu J, Mao J, Duan C, Liang X, Zhu L, Zhu M, Zhang Z, *Lin F(林凡), *Guo R. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.Clin Transl Med. 2022 Jun;12(6):e882. doi: 10.1002/ctm2.882.IF=8.554(共同通讯作者)

 

3.Wu H, Fu H,Wu F,Zhou T,Wang WH,Hu Z,Liang X, *You C, *Sun B, *Lin F(林凡). Activatable autophagy inhibition-primed chemodynamic therapy via targeted sandwich-like two-dimensional nanosheets. Chem Eng J. Journal.Volume 431, Part 4, 1 March 2022, 133470. doi.org/10.1016/j.cej.2021.133470IF=16.744(共同通讯作者)

4.#Hu Z, #Zhou T, *Lin F(林凡).A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells.J Vis Exp. 2021 Mar 28;(169). (IF=1.36)(唯一通讯作者)

 

5.#Chen C, #Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, Chen L, Yan J, Hua Y, *Lin F(林凡). Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors. Mol Cancer Ther. 2020 Oct;19(10):2001-2011. (IF=6.26)(唯一通讯作者)

 

6.#Chen Z, Chen C, Zhou T, Duan C, Wang Q, Zhou X, Zhang X, Wu F, Hua Y, *Lin F(林凡). A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors. Cancer Cell Int. 2020 Jul 23;20:337. (IF=4.2)(唯一通讯作者)

 

7.#Lin F(林凡), #de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, *van Tellingen O.PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models. Clin Cancer Res. 2017 Mar 1;23(5):1286-1298. (IF=10.1)(第一作者)

 

8.#Lin F(林凡), Li Z, Hua Y, *Lim YP. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics. Expert Rev Proteomics. 2016;13(4):411-20. doi: 10.1586/14789450.2016.1164043. (IF=3.90)(第一作者)

 

9.#Lin F(林凡), #Tan H. J., Guan J. S., and *Lim Y. P. Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery. Expert Rev Proteomics. 2014 Mar 31. (IF=3.90)(第一作者)

 

10.#Lin F(林凡), #de Gooijer MC, Moreno Roig E, Buil L, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, *van Tellingen O. ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. Clin Cancer Res. 2014 May 15;20(10):2703-13  (IF=10.1)(第一作者)

 

11.#Lin F(林凡), Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, *van Tellingen O. Abcc4 together with Abcb1 and Abcg2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs. Clin Cancer Res. 2013 Apr 15;19(8):2084-95. (IF=10.1)(第一作者)

 

12.#Lin F(林凡), Hogendijk H, Beijnen JH, *van Tellingen O. Sildenafil is not a useful inhibitor of ABCB1 and ABCG2 in vivo. Eur J Cancer. 2013 May;49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028.(IF=7.3) (第一作者)

 

13.#Lin F(林凡), Buil L, Sherris D, Beijnen JH, *van Tellingen O. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. (IF=5.1) (第一作者)

 

14.#Lin F(林凡), Beijnen JH, van Tellingen O. Targeting on Core (Mutated) Pathways of High-grade Gliomas: Challenges of Intrinsic Resistance and Drug Efflux Transporters. CNS Oncology 2:3, 271-288.(第一作者)

 

15.#Lin F(林凡), Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance

liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012;901:9-17 (IF=3.0) (第一作者)

 

16.#Lin F(林凡), Sherris D, Beijnen JH, van Tellingen O. High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3823-31. (IF=3.0) (第一作者)

 

其他论文:

#Wu L, #Wu W, #Zhang J, #Zhao Z, Li L, Zhu M, Wu M, Wu F, Zhou F, Du Y, Chai RC, Zhang W, Qiu X, Liu Q, Wang Z, Li J, Li K, Chen A, Jiang Y, Xiao X, Zou H, Srivastava R, Zhang T, Cai Y, Liang Y, Huang B, Zhang R, Lin F(林凡), Hu L, Wang X, Qian X, Lv S, Hu B, Zheng S, Hu Z, Shen H, *You Y, *Verhaak RG, *Jiang T, *Wang Q. Natural coevolution of tumor and immunoenvironment in glioblastoma.Cancer Discov. 2022 Sep 19:CD-22-0196. doi: 10.1158/2159-8290.CD-22-0196.(IF=38.272)

#Li D, #Zhang Q, Li L, Chen K, Yang J, Dixit D, Gimple RC, Ci S, Lu C, Hu L, Gao J, Shan D, Li Y, Zhang J, Shi Z, Gu D, Yuan W, Wu Q, Yang K, Zhao L, Qiu Z, Lv D, Gao W, Yang H, Lin F(林凡), Wang Q, Man J, Li C, Tao W, Agnihotri S, Qian X, Shi Y, You Y, *Zhang N, *Rich JN, *Wang X. β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.Cancer Res. 2022 Sep 16;82(18):3321-3334. doi: 10.1158/0008-5472. IF=13.312

#Wang Q, Gao W, Gao F, Jin S, Qu T, Lin F(林凡), Zhang C, Zhang J, Zhang Z, Chen L, *Guo R. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer. 2021 May 25;21(1):602.IF=4.43

#Li W, Wu M, Wang Q, Xu K, Lin F(林凡), Wang Q, *Guo R. A comparative genomics analysis of lung adenocarcinoma for Chinese population by using panel of recurrent mutations. J Biomed Res. 2020 Aug 21;35(1):11-20.

 

#Chaoqun You, Zhiguo Gao, Hongshuai Wu, Kai Sun, Like Ning, Lin F(林凡), Baiwang Sun, Fei Wang*. Reactive oxygen species mediated theranostics using a Fenton reaction activable lipopolymersome J. Mater. Chem. 2018.12 B (IF=5.72)

 

#Zhang G, Chen L, Khan AA, Li B, Gu B, Lin F(林凡), Su X, *Yan J. miRNA-124-3p/neuropilin-1(NRP-1) axis plays an important role in mediating glioblastoma growth and angiogenesis. Int J Cancer. 2018 Aug 1;143(3):635-644. (IF=5.1)

 

Zhang G, Chen L, Chen W, Li B, Yu Y, Lin F(林凡), Guo X, Wang H, Wu G, Gu B, Miao W, Kong J, Jin X, Yi G, You Y, Su X, Gu N. Neural Stem Cells Alleviate Inflammation via Neutralization of IFN- γ Negative Effect in Ischemic Stroke Model.J Biomed Nanotechnol. 2018 Jun 1;14(6):1178-1188.(IF=4.10)

 

#Jiang H, Hu H, Lin F(林凡), Lim YP, Hua Y, Tong X, *Zhang S. S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. Cancer Invest. 2016 Nov 25;34(10):477-488. (IF=2.4)

 

#Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, *Schinkel AH. OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.  Mol Cancer Ther. 2014 Feb;13(2):492-503. IF=5.6

 

#Lagas JS, Lin F(林凡), Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010;16:130-40. (IF=10.1)


授权专利

1. 国家发明专利(2018年):一种抗肿瘤联合药物及其在制备抗癌药物中的应用 (第一发明人,专利号:201811454636.8,已授权)

2. 国家发明专利(2019年):一种PI3KMTH1靶向药组合物及其应用 (第一发明人,专利号:201910653369.5,已授权)